Vor Biopharma Inc. Stock Price, News & Analysis

Vor Bio (Nasdaq: VOR) has presented promising clinical data from its VBP101 study on trem-cel, a genome-edited therapy targeting acute myeloid leukemia (AML). The therapy demonstrated robust engraftment in the first patient five months post-transplant, maintaining hematopoiesis through three cycles of Mylotarg, with no significant adverse effects. The second patient also achieved successful neutrophil engraftment and platelet recovery. Data showed Mylotarg's potential to protect against hematological toxicity and enrich CD33-negative donor cells. Vor Bio plans to escalate Mylotarg doses and submit an IND for VCAR33^ALLO, a new CAR-T therapy, in H1 2023.

Vor Bio (Nasdaq: VOR) announced that clinical data from the initial patient treated in its VBP101 study has been accepted for presentation at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. This Phase 1/2a trial is focused on trem-cel (formerly VOR33) for patients with acute myeloid leukemia (AML). The late-breaking poster presentation, titled "Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT)," will showcase important findings including tolerability of Gemtuzumab Ozogamicin without cytopenias.

Vor Biopharma (Nasdaq: VOR) will participate in B. Riley Securities’ 3rd Annual Oncology Conference, held virtually on January 18, 2023, at 12:00 PM ET. The event aims to showcase advancements in oncology and will include a fireside chat format. A live webcast of the presentation will be accessible on the company's website, with an archived replay available afterward. Vor Biopharma focuses on transforming the standard of care for blood cancer patients through innovative genome engineering of hematopoietic stem cells.

Vor Bio (Nasdaq: VOR) has announced a dual fundraising initiative, pricing an underwritten offering and a private placement, aiming for combined gross proceeds of approximately $115.8 million. The underwritten offering includes 15,302,267 shares at $4.30 per share, expected to yield about $65.8 million, set to close around December 9, 2022. Concurrently, 11,627,907 shares will be sold privately to RA Capital for an additional $50 million. Proceeds will target clinical development and general corporate needs.

Vor Bio has announced promising initial clinical data from its Phase 1/2a trial of trem-cel (formerly VOR33) for acute myeloid leukemia (AML). The first patient's results indicate successful engraftment and maintenance of blood counts after treatment with Mylotarg. A total of 7.6 x10⁶ CD34⁺ cells/kg were infused, achieving 100% donor chimerism and robust hematopoietic reconstitution. No adverse events related to Mylotarg were noted, highlighting the treatment's tolerability. A conference call discussing these developments is scheduled for December 7, 2022.

Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.

Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.

Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:

• Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
• Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
• Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.

Webcasts of these events will be available on Vor Bio's investor section.

Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33^ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.